Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Summary

The National Institutes of Health (NIH) is forecasting a Notice of Funding Opportunity (NOFO) for SBIR Phase IIB Bridge Awards aimed at accelerating the development of cancer-relevant technologies toward commercialization. This is a federal small business innovation research grant opportunity under the R44 activity code, with clinical trials optional. The opportunity is not yet open; it is a forecast notice indicating NIH intends to publish a formal funding announcement. Small businesses with cancer-related technologies progressing from Phase II SBIR toward commercial readiness are the intended applicant pool.

What they want

How they evaluate

Eligibility & certifications

Risks & flags

• This is only a forecast notice — the formal NOFO has not yet been published, so full requirements, deadlines, and evaluation criteria are unknown and subject to change.
• No response due date, award ceiling, or detailed eligibility requirements are provided at this stage.